NCT07577934 Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block
| NCT ID | NCT07577934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin First Central Hospital |
| Condition | Postoperative Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2026-05-10 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2026-05-10 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, randomized, single-blind, parallel-group clinical trial. The study aims to compare the analgesic efficacy of liposomal bupivacaine versus ropivacaine for transversus abdominis plane (TAP) block in patients undergoing laparoscopic cholecystectomy. Eligible participants will be randomly assigned to receive either liposomal bupivacaine or ropivacaine for TAP block during surgery. The primary outcome is the dynamic NRS pain score at 24 hours after surgery. Secondary outcomes include static and dynamic NRS pain scores at multiple time points, QoR-15 recovery quality, time to first rescue analgesia, analgesic consumption, gastrointestinal function recovery, length of hospital stay, and adverse events. Participants will be followed up to 3 months after surgery to evaluate the incidence of chronic post-surgical pain (CPSP). All participants will receive routine clinical care, and participation is voluntary.
Eligibility Criteria
Inclusion Criteria: * Age 18-65 years, either gender. * Patients scheduled for elective laparoscopic cholecystectomy. * ASA physical status I-III. * Able to provide written informed consent and complete the 3-month follow-up. Exclusion Criteria: * History of allergy to local anesthetics. * History of dementia, psychosis, or other central nervous system diseases. * History of chronic pain or long-term use of opioids or other analgesics. * Contraindications to nerve block: infection at puncture site, severe coagulopathy. * Severe hepatic or renal dysfunction, pregnancy, or lactation.
Contact & Investigator
Wenli Yu
STUDY DIRECTOR
Tianjin First Central Hospital
Frequently Asked Questions
Who can join the NCT07577934 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07577934 currently recruiting?
Yes, NCT07577934 is actively recruiting participants. Contact the research team at m456365zky@163.com for enrollment information.
Where is the NCT07577934 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07577934 clinical trial?
NCT07577934 is sponsored by Tianjin First Central Hospital. The principal investigator is Wenli Yu at Tianjin First Central Hospital. The trial plans to enroll 86 participants.